AbbVie Inc. (NYSE:ABBV) Shares Sold by Norway Savings Bank

Norway Savings Bank trimmed its holdings in shares of AbbVie Inc. (NYSE:ABBVFree Report) by 17.1% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,035 shares of the company’s stock after selling 832 shares during the period. Norway Savings Bank’s holdings in AbbVie were worth $544,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Kalos Management Inc. acquired a new position in shares of AbbVie during the first quarter worth $26,000. Boulder Wealth Advisors LLC acquired a new position in shares of AbbVie during the fourth quarter worth $31,000. Stone House Investment Management LLC acquired a new position in shares of AbbVie during the first quarter worth $37,000. True Wealth Design LLC bought a new stake in shares of AbbVie in the fourth quarter worth $39,000. Finally, General Partner Inc. bought a new stake in shares of AbbVie in the first quarter worth $40,000. 67.86% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts recently issued reports on ABBV shares. StockNews.com started coverage on shares of AbbVie in a research note on Thursday, August 17th. They issued a “strong-buy” rating for the company. TheStreet upgraded shares of AbbVie from a “c+” rating to a “b” rating in a research note on Monday, August 28th. Piper Jaffray Companies lifted their price target on shares of AbbVie from $163.00 to $170.00 and gave the stock an “overweight” rating in a research note on Friday, July 28th. HSBC began coverage on shares of AbbVie in a research note on Friday, July 14th. They issued a “buy” rating and a $167.00 price target for the company. Finally, William Blair began coverage on shares of AbbVie in a research note on Tuesday, July 25th. They set a “market perform” rating for the company. Eight equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $165.79.

Check Out Our Latest Stock Report on ABBV

Insider Buying and Selling

In related news, CEO Richard A. Gonzalez sold 18,500 shares of the company’s stock in a transaction dated Monday, July 31st. The shares were sold at an average price of $149.15, for a total value of $2,759,275.00. Following the completion of the sale, the chief executive officer now owns 625,294 shares of the company’s stock, valued at $93,262,600.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.26% of the company’s stock.

AbbVie Stock Up 1.2 %

AbbVie stock opened at $153.93 on Tuesday. The company has a 50-day simple moving average of $146.42 and a 200-day simple moving average of $147.44. The firm has a market capitalization of $271.69 billion, a P/E ratio of 31.67, a P/E/G ratio of 2.79 and a beta of 0.58. The company has a debt-to-equity ratio of 4.33, a quick ratio of 0.77 and a current ratio of 0.89. AbbVie Inc. has a one year low of $130.96 and a one year high of $168.11.

AbbVie (NYSE:ABBVGet Free Report) last released its quarterly earnings results on Thursday, July 27th. The company reported $2.91 EPS for the quarter, topping the consensus estimate of $2.79 by $0.12. The business had revenue of $13.87 billion during the quarter, compared to analyst estimates of $13.52 billion. AbbVie had a net margin of 15.50% and a return on equity of 151.29%. As a group, equities analysts expect that AbbVie Inc. will post 11.03 earnings per share for the current year.

AbbVie Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, November 15th. Investors of record on Friday, October 13th will be issued a $1.48 dividend. This represents a $5.92 annualized dividend and a yield of 3.85%. The ex-dividend date is Thursday, October 12th. AbbVie’s payout ratio is currently 121.81%.

About AbbVie

(Free Report)

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Beh├žet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies.

Further Reading

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBVFree Report).

Institutional Ownership by Quarter for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.